Biofrontera AG: Biofrontera Signs Distribution Agreement with Propaira Pty Ltd for Ameluz® in Australia

Leverkusen (pta009/09.11.2026/09:30 UTC+1)

Leverkusen, November 9, 2026 – Biofrontera AG (ISIN: DE000A4BGGM7), an international biopharmaceutical company specializing in dermatology, today announced the signing of a distribution agreement with Propaira Pty Ltd, an Australian dermatology company, for the commercialization of Ameluz® in Australia.

The agreement represents an important step in Biofrontera's strategy to expand the international presence of Ameluz® and unlock new growth opportunities beyond its established markets. Following the return of the commercial rights for Oceania by Maruho in April 2026, Biofrontera has actively pursued new partnerships in the region. The agreement with Propaira marks the first achievement of this initiative and establishes a foundation for the Company's ambition to progressively expand its commercial presence across the main markets in Oceania over the coming years.

Australia offers significant market potential for Ameluz®

Australia represents a particularly attractive market for dermatological treatments due to its high levels of ultraviolet radiation exposure and the significant prevalence of sun-related skin conditions.

Actinic keratosis (AK), a precancerous skin condition associated with long-term sun exposure, is particularly common in Australia, with studies estimating a prevalence of 40% to 60% among the fair-skinned Australian population aged over 40. In addition, Australia has one of the world's highest burdens of non-melanoma skin cancer, including basal cell carcinoma (BCC). According to the Australian Institute of Health and Welfare, approximately 535,000 Australians undergo surgical removal of at least one non-melanoma skin cancer each year.

These epidemiological characteristics highlight the considerable potential for photodynamic therapy (PDT) as a treatment option for eligible patients and underline the strategic attractiveness of Australia for Ameluz®.

Propaira Pty Ltd, founded in 2010 and headquartered in Melbourne, is an Australian dermatology company specializing in the research, development and commercialization of products addressing a wide range of skin conditions. Founded by Baz Hamo, who brings extensive experience in pharmaceutical science, formulation and clinical skin care, Propaira has developed a diversified dermatology portfolio and established a presence in the Australian dermatology community. Its focus on innovation, product quality and addressing unmet dermatological needs makes Propaira a well-suited partner to support the introduction and long-term development of Ameluz® in Australia.

Axel Drews, Vice President Global Sales & Marketing of Biofrontera Pharma GmbH, commented:

"We see significant potential for Ameluz® in Australia, a market characterized by an exceptionally high prevalence of actinic keratosis and non-melanoma skin cancer. The strong interest we have received from a well-established local dermatology partner such as Propaira, just a few months after regaining the commercial rights for Oceania, reinforces our confidence in the attractiveness of our product and the opportunities offered by this market. We believe Propaira's dermatology expertise and local market knowledge provide an excellent foundation for successfully developing the Ameluz® business in Australia."

Pilar de la Huerta Martínez, CFO and Managing Director of Biofrontera AG, added:

"This agreement is another tangible step in the execution of our growth strategy. We are strongly committed to expanding the international footprint of Ameluz® by entering new markets and building partnerships with established local players. At the same time, we continue to pursue opportunities to broaden our dermatology portfolio through licensing agreements and selective acquisitions. Combining geographical expansion with portfolio diversification is a key pillar of our strategy to drive sustainable growth and strengthen Biofrontera's position in the international dermatology market over the coming years."

The agreement with Propaira represents the first step in Biofrontera's renewed commercial expansion across Oceania. The Company intends to explore additional opportunities in other key markets in the region, building on the commercial rights recovered in April 2026. Upon successful registration of the product by our partner Propaira, commercialization of Ameluz® is intended to in the first half of 2028.

About Propaira Pty Ltd

Propaira Pty Ltd is an Australian dermatology company founded in 2010 and based in Melbourne. The company specializes in the research, development and commercialization of dermatological products addressing a broad range of skin conditions. Founded by Baz Hamo, Propaira combines expertise in pharmaceutical science, formulation and clinical skin care with a commitment to product quality, innovation and sustainability. Its products are developed and manufactured in accordance with applicable quality standards, including GMP and ISO guidelines.

Further information: www.propaira.com

About Biofrontera

Biofrontera AG is a biopharmaceutical company founded in 1997 that specializes in the development and distribution of dermatological drugs. Based in Germany, the Company develops and markets innovative products for the treatment of the skin. The Company's leading product is Ameluz®, a prescription topical drug used in photodynamic therapy for certain superficial skin cancers and their precursors. Ameluz® has been marketed in the EU since 2012. Biofrontera is one of the first German biopharmaceutical companies to have received a centralized European approval as well as an approval in the United Kingdom for a drug it developed in-house.

(end)

Emitter:	Biofrontera AG Hemmelrather Weg 201 51377 Leverkusen Germany
Contact Person:	Investor Relations
Phone:	+49 (0) 214 87 63 20
E-Mail:	ir@biofrontera.com
Website:	www.biofrontera.com
ISIN(s):	DE000A4BGGM7 (Share)
Stock Exchange(s):	Regulated Market in Dusseldorf, Frankfurt; Free Market in Munich, Stuttgart, Tradegate BSX